September 19, 2022 by Jon Hennessey RIVUS_PHARMACEUTICALS_ANNOUNCES_POSITIVE_DATA_FROM_PHASE_2A_CLINICAL_TRIAL_OF_LEAD_CANDIDATE_HU6-1